Systemic Inflammation Predicts All-Cause Mortality: A Glasgow Inflammation Outcome Study

Introduction Markers of the systemic inflammatory response, including C-reactive protein and albumin (combined to form the modified Glasgow Prognostic Score), as well as neutrophil, lymphocyte and platelet counts have been shown to be prognostic of survival in patients with cancer. The aim of the present study was to examine the prognostic relationship between these markers of the systemic inflammatory response and all-cause, cancer, cardiovascular and cerebrovascular mortality in a large incidentally sampled cohort. Methods Patients (n = 160 481) who had an incidental blood sample taken between 2000 and 2008 were studied for the prognostic value of C-reactive protein (>10mg/l, albumin (>35mg/l), neutrophil (>7.5×109/l) lymphocyte and platelet counts. Also, patients (n = 52 091) sampled following the introduction of high sensitivity C-reactive protein (>3mg/l) measurements were studied. A combination of these markers, to make cumulative inflammation-based scores, were investigated. Results In all patients (n = 160 481) C-reactive protein (>10mg/l) (HR 2.71, p<0.001), albumin (>35mg/l) (HR 3.68, p<0.001) and neutrophil counts (HR 2.18, p<0.001) were independently predictive of all-cause mortality. These associations were also observed in cancer, cardiovascular and cerebrovascular mortality before and after the introduction of high sensitivity C-reactive protein measurements (>3mg/l) (n = 52 091). A combination of high sensitivity C-reactive protein (>3mg/l), albumin and neutrophil count predicted all-cause (HR 7.37, p<0.001, AUC 0.723), cancer (HR 9.32, p<0.001, AUC 0.731), cardiovascular (HR 4.03, p<0.001, AUC 0.650) and cerebrovascular (HR 3.10, p<0.001, AUC 0.623) mortality. Conclusion The results of the present study showed that an inflammation-based prognostic score, combining high sensitivity C-reactive protein, albumin and neutrophil count is prognostic of all-cause mortality.

[1]  Beth A. Glenn,et al.  Cluster-Randomized Trial to Increase Hepatitis B Testing among Koreans in Los Angeles , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[2]  D. McMillan,et al.  Cancer and systemic inflammation: treat the tumour and treat the host , 2014, British Journal of Cancer.

[3]  Jennifer L. Gay,et al.  Meeting Physical Activity Guidelines is Associated with Lower Allostatic Load and Inflammation in Mexican Americans , 2015, Journal of Immigrant and Minority Health.

[4]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[5]  D. McMillan,et al.  Cancer and systemic inflammation: stage the tumour and stage the host , 2013, British Journal of Cancer.

[6]  D. McMillan.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[7]  D. Talwar,et al.  Optimization of the systemic inflammation‐based Glasgow Prognostic Score , 2013, Cancer.

[8]  P. Libby,et al.  Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study , 2013, Journal of the American Heart Association.

[9]  Y. Toiyama,et al.  Prognostic Significance of a Systemic Inflammatory Response in Patients Undergoing Multimodality Therapy for Advanced Colorectal Cancer , 2012, Oncology.

[10]  H. Yoon,et al.  High-Sensitivity C-Reactive Protein Levels and Cancer Mortality , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[11]  D. Faeh,et al.  Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III , 2012, BMC Public Health.

[12]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[13]  D. McMillan,et al.  Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems , 2011, British Journal of Cancer.

[14]  T. Todenhöfer,et al.  Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C‐reactive protein and standard pathological risk factors: the TNR‐C score , 2011, BJU international.

[15]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[16]  D. Maestripieri,et al.  Chronic stress, allostatic load, and aging in nonhuman primates , 2011, Development and Psychopathology.

[17]  D. Carroll,et al.  Lymphocyte cell counts in middle age are positively associated with subsequent all-cause and cardiovascular mortality. , 2011, QJM : monthly journal of the Association of Physicians.

[18]  Hong-Kyu Kim,et al.  High-Sensitivity C-Reactive Protein and Cancer , 2011, Journal of epidemiology.

[19]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[20]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Journal of the American College of Cardiology.

[21]  D. Talwar,et al.  The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study , 2010, British Journal of Cancer.

[22]  B. Nordestgaard,et al.  C-reactive protein and all-cause mortality--the Copenhagen City Heart Study. , 2010, European heart journal.

[23]  H. Haslacher,et al.  Sex differences in the association between albumin and all‐cause and vascular mortality , 2009, European journal of clinical investigation.

[24]  P. Koudstaal,et al.  C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death , 2009, Journal of Neurology.

[25]  P. Ridker.  High-sensitivity C-reactive protein as a predictor of all-cause mortality: implications for research and patient care. , 2008, Clinical chemistry.

[26]  Georg Endler,et al.  C-reactive protein and all-cause mortality in a large hospital-based cohort. , 2008, Clinical chemistry.

[27]  R. Gillum,et al.  Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. , 2005, Annals of epidemiology.

[28]  Paul M Ridker,et al.  C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke , 2003, Circulation.

[29]  R. Bonow,et al.  Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. , 2001, American heart journal.

[30]  M. Di Napoli,et al.  C-Reactive Protein in Ischemic Stroke: An Independent Prognostic Factor , 2001, Stroke.

[31]  P. Goldwasser,et al.  Association of serum albumin and mortality risk. , 1997, Journal of clinical epidemiology.

[32]  A. Pasternack,et al.  Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. , 1996, European heart journal.

[33]  N. Wadhwa,et al.  Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis. , 1994, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.